Supplementary Table I. Second-line treatments.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | All (N=58) | IO-IO (n=45) | IO-TKI (n=13) |
| 2nd-line treatment, N (%) | |  |  |  |
|  | Axitinib | 17 (29.3) | 13 (28.9) | 4 (30.8) |
|  | Cabozantinib | 35 (60.3) | 30 (66.7) | 5 (38.5) |
|  | Pazopanib | 1 (1.7) | 0 (0.0) | 1 (7.7) |
|  | Sorafenib | 1 (1.7) | 1 (2.2) | 0 (0.0) |
|  | Nivolumab | 2 (3.4) | 0 (0.0) | 2 (15.4) |
|  | Others | 2 (3.4) | 1 (2.2) | 1 (7.7) |

IO, Immune-oncologic drug; TKI, tyrosine kinase inhibitor.